You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAntipyrine
Accession NumberDB01435
TypeSmall Molecule
GroupsApproved
DescriptionAn analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Structure
Thumb
Synonyms
1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one
2,3-Dimethyl-1-phenyl-5-pyrazolone
Analgesine
Antipyrine
Fenazon
Fenazona
Phenazon
Phenazone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Acella Antipyrine and Benzocaine OticACELLA PHARMACEUTICALS
Antidouleurs RezallProduits Francais Labs Inc.
Antipyrine and BenzocaineRebel Distributors Corp
Antipyrine and Benzocaine OticACELLA PHARMACEUTICALS
AuralganPaladin Labs Inc
Auralgan EardropsWyeth Canada
Auralgan SolutionWyeth Consumer Healthcare Inc.
Aurax OticAcella Pharmaceuticals, LLC
AurodexMajor Pharmaceuticals
Formule L2Herbages Naturbec LtÉe.
Oti CalProduits Francais Labs Inc.
Otic Care Antipyrine and BenzocainePure Tek Corporation
OtozinAllegis Pharmaceuticals, LLC
SaltsNot Available
Categories
UNIIT3CHA1B51H
CAS number60-80-0
WeightAverage: 188.2258
Monoisotopic: 188.094963016
Chemical FormulaC11H12N2O
InChI KeyVEQOALNAAJBPNY-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
IUPAC Name
1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one
SMILES
CN1N(C(=O)C=C1C)C1=CC=CC=C1
Pharmacology
IndicationAntipyrine is an analgesic often used to test effects of other drugs on liver enzymes..
Structured Indications Not Available
PharmacodynamicsAntipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Mechanism of actionAntipyrine is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinunknown
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Antipyrine
NorantipyrineDetails
Antipyrine
3-HydroxymethylantipyrineDetails
Antipyrine
4-HydroxyantipyrineDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Antipyrine Action PathwayDrug actionSMP00692
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Antipyrine is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Antipyrine is combined with 5-androstenedione.Experimental, Illicit
AbciximabAntipyrine may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Antipyrine can be increased when it is combined with Abiraterone.Approved
AcebutololAntipyrine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aceclofenac.Approved
AcenocoumarolAntipyrine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Antipyrine.Approved, Vet Approved
AclarubicinAntipyrine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Antipyrine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.Approved
AliskirenAntipyrine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololAntipyrine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Antipyrine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Amcinonide.Approved
AmikacinAntipyrine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAntipyrine may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Antipyrine can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinAntipyrine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAntipyrine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Antipyrine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Anisodamine.Investigational
annamycinAntipyrine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
Antithrombin III humanAntipyrine may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Antipyrine may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanAntipyrine may increase the anticoagulant activities of Apixaban.Approved
ApramycinAntipyrine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Antipyrine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinAntipyrine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinAntipyrine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanAntipyrine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Antipyrine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololAntipyrine may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe metabolism of Antipyrine can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Antipyrine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAntipyrine may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Antipyrine can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.Approved
AzithromycinThe metabolism of Antipyrine can be decreased when combined with Azithromycin.Approved
BalsalazideAntipyrine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAntipyrine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAntipyrine may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Antipyrine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Antipyrine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Antipyrine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betulinic Acid.Investigational
BevantololAntipyrine may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Antipyrine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Antipyrine.Approved, Investigational
BisoprololAntipyrine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAntipyrine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Antipyrine can be decreased when combined with Boceprevir.Approved
BopindololAntipyrine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Antipyrine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Antipyrine can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Bucillamine.Investigational
BucindololAntipyrine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Budesonide.Approved
BufuralolAntipyrine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideAntipyrine may decrease the diuretic activities of Bumetanide.Approved
BupranololAntipyrine may decrease the antihypertensive activities of Bupranolol.Approved
BupropionThe metabolism of Antipyrine can be decreased when combined with Bupropion.Approved
CaffeineThe metabolism of Antipyrine can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Antipyrine.Experimental
CapecitabineThe metabolism of Antipyrine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Antipyrine.Approved
CarbamazepineThe metabolism of Antipyrine can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Antipyrine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Antipyrine.Approved, Vet Approved, Withdrawn
CarteololAntipyrine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAntipyrine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Celecoxib.Approved, Investigational
CeliprololAntipyrine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Antipyrine can be increased when it is combined with Ceritinib.Approved
CertoparinAntipyrine may increase the anticoagulant activities of Certoparin.Approved
ChloramphenicolThe metabolism of Antipyrine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Antipyrine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.Approved, Vet Approved
ChlorpromazineThe metabolism of Antipyrine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Antipyrine.Approved
CholecalciferolThe metabolism of Antipyrine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Antipyrine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Antipyrine.Approved
CimetidineThe metabolism of Antipyrine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Antipyrine can be decreased when combined with Cinacalcet.Approved
CinoxacinAntipyrine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinAntipyrine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Antipyrine can be decreased when combined with Citalopram.Approved
Citric AcidAntipyrine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Antipyrine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Antipyrine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Antipyrine can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clodronate.Approved, Investigational, Vet Approved
ClomipramineThe metabolism of Antipyrine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clonixin.Approved
ClopidogrelThe metabolism of Antipyrine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Antipyrine.Vet Approved
ClotrimazoleThe metabolism of Antipyrine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Antipyrine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Antipyrine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Antipyrine can be decreased when combined with Cocaine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Antipyrine can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Antipyrine can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Antipyrine is combined with Curcumin.Investigational
CyclosporineAntipyrine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Antipyrine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Antipyrine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Antipyrine is combined with D-Limonene.Investigational
Dabigatran etexilateAntipyrine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.Approved
DalteparinAntipyrine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAntipyrine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Antipyrine.Approved, Investigational
DarifenacinThe metabolism of Antipyrine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Antipyrine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Antipyrine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinAntipyrine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Antipyrine can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Antipyrine is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Antipyrine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Antipyrine can be decreased when combined with Desipramine.Approved
DesirudinAntipyrine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Antipyrine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Antipyrine.Approved
DextranAntipyrine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Antipyrine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Antipyrine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Antipyrine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine.Approved, Vet Approved
DicoumarolAntipyrine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Antipyrine.Approved
DihydroergotamineThe metabolism of Antipyrine can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinAntipyrine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Antipyrine can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Antipyrine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Antipyrine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Antipyrine.Approved
DiphenhydramineThe metabolism of Antipyrine can be decreased when combined with Diphenhydramine.Approved
DisulfiramThe metabolism of Antipyrine can be decreased when combined with Disulfiram.Approved
DoxorubicinAntipyrine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Antipyrine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Antipyrine can be decreased when combined with Dronedarone.Approved
DrospirenoneAntipyrine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Droxicam.Approved
DuloxetineThe metabolism of Antipyrine can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Antipyrine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ebselen.Investigational
Edetic AcidAntipyrine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAntipyrine may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Antipyrine can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Antipyrine can be decreased when combined with Eliglustat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Antipyrine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Antipyrine.Approved
EnoxacinAntipyrine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinAntipyrine may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Antipyrine is combined with Epirizole.Approved
EpirubicinAntipyrine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAntipyrine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.Approved
EquileninThe risk or severity of adverse effects can be increased when Antipyrine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Equilin.Approved
ErythromycinThe metabolism of Antipyrine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Antipyrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololAntipyrine may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Antipyrine can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone sulfate.Approved
Etacrynic acidAntipyrine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.Approved, Investigational
Ethyl biscoumacetateAntipyrine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Antipyrine can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Antipyrine is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Antipyrine is combined with exisulind.Investigational
FelodipineThe metabolism of Antipyrine can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Antipyrine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Antipyrine.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.Approved
FleroxacinAntipyrine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Antipyrine.Approved, Withdrawn
FloxuridineThe metabolism of Antipyrine can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with fluasterone.Investigational
FluconazoleThe metabolism of Antipyrine can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fludrocortisone.Approved
FluindioneAntipyrine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAntipyrine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Antipyrine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Antipyrine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Antipyrine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Antipyrine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Antipyrine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Antipyrine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Antipyrine.Approved, Nutraceutical, Vet Approved
FondaparinuxAntipyrine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAntipyrine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Antipyrine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Antipyrine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Antipyrine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Antipyrine.Approved
FosphenytoinThe metabolism of Antipyrine can be increased when combined with Fosphenytoin.Approved
FramycetinAntipyrine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAntipyrine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Antipyrine can be increased when it is combined with Fusidic Acid.Approved
GabexateAntipyrine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAntipyrine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAntipyrine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Antipyrine.Approved, Withdrawn
GemfibrozilThe metabolism of Antipyrine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAntipyrine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAntipyrine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAntipyrine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAntipyrine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinAntipyrine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Antipyrine is combined with HE3286.Investigational
HeparinAntipyrine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Higenamine.Investigational
HirulogAntipyrine may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Antipyrine is combined with HMPL-004.Investigational
HydralazineAntipyrine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Antipyrine.Approved
Hygromycin BAntipyrine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Antipyrine is combined with Icatibant.Approved
IdarubicinAntipyrine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Antipyrine can be increased when it is combined with Idelalisib.Approved
idraparinuxAntipyrine may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.Approved, Investigational
ImatinibThe metabolism of Antipyrine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Antipyrine.Investigational
ImipramineThe metabolism of Antipyrine can be decreased when combined with Imipramine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.Approved
IndenololAntipyrine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Antipyrine can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Indoprofen.Withdrawn
INNO-206Antipyrine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Antipyrine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Antipyrine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Antipyrine can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Antipyrine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Antipyrine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Antipyrine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Antipyrine can be increased when it is combined with Ivacaftor.Approved
KanamycinAntipyrine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Antipyrine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Antipyrine.Approved
LabetalolAntipyrine may decrease the antihypertensive activities of Labetalol.Approved
LapatinibThe metabolism of Antipyrine can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Antipyrine.Approved, Investigational
LeflunomideThe metabolism of Antipyrine can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinAntipyrine may increase the anticoagulant activities of Lepirudin.Approved
LevobunololAntipyrine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAntipyrine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Antipyrine can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Antipyrine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Antipyrine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Antipyrine.Approved
LomefloxacinAntipyrine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Antipyrine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Antipyrine can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.Approved
LosartanThe metabolism of Antipyrine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Antipyrine can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Antipyrine.Approved, Investigational
LuliconazoleThe serum concentration of Antipyrine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Antipyrine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Antipyrine can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Antipyrine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Antipyrine.Approved
ME-609The risk or severity of adverse effects can be increased when Antipyrine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Antipyrine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.Approved, Vet Approved
MesalazineAntipyrine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Antipyrine is combined with Metamizole.Withdrawn
MethadoneThe metabolism of Antipyrine can be decreased when combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Antipyrine.Approved
MethotrimeprazineThe metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAntipyrine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Antipyrine.Approved, Investigational
MetrizamideAntipyrine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Antipyrine can be decreased when combined with Mexiletine.Approved
MifepristoneThe serum concentration of Antipyrine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Antipyrine can be decreased when combined with Mirabegron.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Antipyrine.Approved
MitotaneThe serum concentration of Antipyrine can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Antipyrine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Antipyrine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Antipyrine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Antipyrine.Approved
MoxifloxacinAntipyrine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nabumetone.Approved
NadololAntipyrine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAntipyrine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAntipyrine may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Antipyrine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Antipyrine.Approved
Nalidixic AcidAntipyrine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Antipyrine is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Antipyrine is combined with NCX 4016.Investigational
NeamineAntipyrine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Antipyrine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Antipyrine can be decreased when combined with Nelfinavir.Approved
NemonoxacinAntipyrine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAntipyrine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nepafenac.Approved
NetilmicinAntipyrine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Antipyrine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Antipyrine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Antipyrine can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Antipyrine can be decreased when combined with Nicotine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Antipyrine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.Approved, Withdrawn
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Antipyrine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nitroaspirin.Investigational
NorfloxacinAntipyrine may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinAntipyrine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Antipyrine can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Antipyrine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.Approved
OlsalazineAntipyrine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Antipyrine.Investigational
OmeprazoleThe metabolism of Antipyrine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Antipyrine can be increased when it is combined with Osimertinib.Approved
OtamixabanAntipyrine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.Approved
OxprenololAntipyrine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oxyphenbutazone.Withdrawn
PalbociclibThe serum concentration of Antipyrine can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Antipyrine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Antipyrine can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Parecoxib.Approved
ParomomycinAntipyrine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Antipyrine can be decreased when combined with Paroxetine.Approved, Investigational
PazufloxacinAntipyrine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAntipyrine may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAntipyrine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Antipyrine can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateAntipyrine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Antipyrine.Approved
PhenindioneAntipyrine may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Antipyrine can be increased when combined with Phenobarbital.Approved
PhenprocoumonAntipyrine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Antipyrine.Approved, Vet Approved
PhenytoinThe metabolism of Antipyrine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.Approved, Investigational
PindololAntipyrine may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Antipyrine can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinAntipyrine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAntipyrine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.Approved, Investigational
PlicamycinAntipyrine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Antipyrine.Approved
PosaconazoleThe metabolism of Antipyrine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololAntipyrine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Antipyrine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pregnenolone.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Antipyrine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Antipyrine can be increased when it is combined with Probenecid.Approved
PromazineThe metabolism of Antipyrine can be decreased when combined with Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Propacetamol.Approved
PropranololAntipyrine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Antipyrine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Antipyrine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Antipyrine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Antipyrine.Vet Approved
Protein CAntipyrine may increase the anticoagulant activities of Protein C.Approved
Protein S humanAntipyrine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAntipyrine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAntipyrine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Antipyrine is combined with PTC299.Investigational
PuromycinAntipyrine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Antipyrine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Antipyrine can be increased when it is combined with Quazepam.Approved, Illicit
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Antipyrine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Antipyrine.Approved
QuinidineThe metabolism of Antipyrine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Antipyrine can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Antipyrine can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Antipyrine.Approved
RanolazineThe metabolism of Antipyrine can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Antipyrine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.Experimental, Investigational
ReviparinAntipyrine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinAntipyrine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Antipyrine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Antipyrine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Antipyrine can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Antipyrine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanAntipyrine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Antipyrine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Antipyrine can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Antipyrine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinAntipyrine may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Antipyrine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Antipyrine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Antipyrine.Experimental
SaquinavirThe metabolism of Antipyrine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Antipyrine.Investigational
SecobarbitalThe metabolism of Antipyrine can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Seratrodast.Approved, Investigational
SertralineThe metabolism of Antipyrine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Antipyrine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Antipyrine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Antipyrine can be increased when it is combined with Simeprevir.Approved
SisomicinAntipyrine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Antipyrine is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Antipyrine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolAntipyrine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAntipyrine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAntipyrine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinAntipyrine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Antipyrine.Approved
SpironolactoneAntipyrine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Antipyrine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Antipyrine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Antipyrine can be increased when it is combined with Stiripentol.Approved
StreptomycinAntipyrine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAntipyrine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Antipyrine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Antipyrine can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineAntipyrine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Antipyrine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Antipyrine.Approved
SulodexideAntipyrine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Antipyrine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.Approved, Withdrawn
TacrolimusAntipyrine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Antipyrine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Antipyrine.Approved
TamoxifenThe metabolism of Antipyrine can be decreased when combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Antipyrine.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Antipyrine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Antipyrine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.Approved, Investigational
TemafloxacinAntipyrine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Antipyrine.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Antipyrine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tepoxalin.Vet Approved
TerbinafineThe metabolism of Antipyrine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Antipyrine can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Antipyrine.Approved
ThiotepaThe metabolism of Antipyrine can be decreased when combined with Thiotepa.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Antipyrine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Antipyrine can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiludronate.Approved, Vet Approved
TimololAntipyrine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tinoridine.Investigational
TipranavirThe metabolism of Antipyrine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tixocortol.Approved
TobramycinAntipyrine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Antipyrine can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.Approved
TopiramateThe metabolism of Antipyrine can be decreased when combined with Topiramate.Approved
TorasemideAntipyrine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Antipyrine.Approved
TranilastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Antipyrine can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAntipyrine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Antipyrine.Approved, Vet Approved
TrimethoprimThe metabolism of Antipyrine can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Antipyrine.Approved
TrovafloxacinAntipyrine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Antipyrine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Antipyrine can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinAntipyrine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Antipyrine can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Antipyrine.Approved
VemurafenibThe serum concentration of Antipyrine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Antipyrine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Antipyrine can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Antipyrine can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinAntipyrine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAntipyrine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Antipyrine may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Antipyrine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Antipyrine.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Antipyrine can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zomepirac.Withdrawn
ZorubicinAntipyrine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Andreas Burgard, “Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use.” U.S. Patent US20030008865, issued January 09, 2003.

US20030008865
General ReferencesNot Available
External Links
ATC CodesN02BB51N02BB71N02BB01S02DA03
AHFS Codes
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9931
Caco-2 permeable+0.8273
P-glycoprotein substrateNon-substrate0.8995
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8737
Renal organic cation transporterNon-inhibitor0.8837
CYP450 2C9 substrateNon-substrate0.6871
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6459
CYP450 1A2 substrateNon-inhibitor0.8617
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9444
CYP450 2C19 inhibitorNon-inhibitor0.9533
CYP450 3A4 inhibitorNon-inhibitor0.9615
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7357
Ames testNon AMES toxic0.9261
CarcinogenicityNon-carcinogens0.9202
BiodegradationNot ready biodegradable0.9761
Rat acute toxicity2.0746 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9816
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidTopical
Solution / dropsAuricular (otic)
SolutionAuricular (otic)
LiquidOral
SolutionTopical
Prices
Unit descriptionCostUnit
Auralgan ear drops13.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114 °CPhysProp
boiling point319 °CPhysProp
water solubility5.19E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.38HANSCH,C ET AL. (1995)
Caco2 permeability-4.55ADME Research, USCD
pKa1.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility47.4 mg/mLALOGPS
logP1.18ALOGPS
logP1.22ChemAxon
logS-0.6ALOGPS
pKa (Strongest Basic)0.37ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability20.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.41 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassPyrazoles
Direct ParentPhenylpyrazoles
Alternative Parents
Substituents
  • Phenylpyrazole
  • Benzenoid
  • Pyrazolinone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. [PubMed:11695253 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. [PubMed:11695253 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on July 26, 2007 04:19 / Updated on August 17, 2016 12:23